Neovascular Age-related Macular Degeneration Treatment Market
Market Insights on Neovascular Age-related Macular Degeneration Treatment covering sales outlook, demand forecast & up-to-date key trends.
Neovascular Age-related Macular Degeneration Treatment Market by Disease Type, Drug Type, Age Group, Gender, Stage of Disease, Distribution Channel & Region | Forecast 2023 to 2033
Neovascular Age-related Macular Degeneration Treatment Market Snapshot (2023 to 2033)
The global neovascular age-related macular degeneration treatment market is expected to garner a market value of US$ 3 billion in 2023 and is expected to accumulate a market value of US$ 4.89 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for neovascular age-related macular degeneration treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Neovascular Age-related Macular Degeneration Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. Neovascular age-related macular degeneration is a serious eye condition that affects older adults and can lead to vision loss. The treatment of nAMD typically involves medications that are injected into the eye to stop the growth of abnormal blood vessels in the retina. These medications are known as anti-VEGF drugs.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 3 billion |
|
Anticipated Forecast Value (2033) |
US$ 4.89 billion |
|
Projected Growth Rate (2023 to 2033) |
5% CAGR |
Customize this Report
Let us know your requirement to get
100% FREE customization
2018 to 2022 Neovascular Age-related Macular Degeneration Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for Neovascular Age-related Macular Degeneration Treatment reflected a value of 3.5% during the historical period, 2018 to 2022.
The neovascular age-related macular degeneration treatment market has been growing rapidly in recent years due to the increasing prevalence of nAMD and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.
The key players in the neovascular age-related macular degeneration treatment market include pharmaceutical companies such as Roche, Novartis, Regeneron, and Bayer. These companies are investing heavily in research and development to bring new and improved drugs to market for the treatment of nAMD. In addition to anti-VEGF drugs, other treatments for nAMD are also being developed, including gene therapy and sustained-release drug delivery systems. These new treatments have the potential to improve patient outcomes and reduce the need for frequent injections.
Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Neovascular Age-related Macular Degeneration Treatment market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones. The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. Overall, the market for neovascular age-related macular degeneration treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Neovascular Age-related Macular Degeneration Treatment Market?
Growing Awareness along with increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth
The neovascular age-related macular degeneration (nAMD) treatment market has been experiencing significant growth in recent years and is expected to continue growing in the coming years. Several factors are driving this growth, including:
- Increasing prevalence of nAMD: As the global population ages, the prevalence of nAMD is increasing. According to the World Health Organization, the number of people aged 65 years and older is projected to triple by 2050, which will lead to an increase in the number of nAMD cases.
- Advancements in treatment options: The introduction of anti-VEGF drugs has revolutionized the treatment of nAMD. These drugs have been shown to be highly effective in halting the growth of abnormal blood vessels in the retina, which can prevent vision loss in patients with nAMD.
- Rising healthcare expenditure: As healthcare expenditure continues to rise, more resources are being allocated towards the development and adoption of new nAMD treatments. This has led to an increase in research and development activities, as well as greater patient access to new and innovative treatments.
Sabyasachi Ghosh
Principal Consultant
Talk to Analyst
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Neovascular Age-related Macular Degeneration Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The cost of nAMD treatment with anti-VEGF drugs can be very high, and this can limit patient access to these treatments. Some patients may not be able to afford the cost of treatment, while others may face limitations in their insurance coverage.
Moreover, Anti-VEGF drugs are typically administered through injections directly into the eye, which can be uncomfortable and inconvenient for patients. Additionally, these injections need to be given on a regular basis, which can be challenging for patients who have difficulty traveling to clinics or for those who may be homebound.
Region-Wise Insights
How is the Neovascular Age-related Macular Degeneration Treatment Market Turning Out in the South & East Asia Regions?
Increasing awareness and diagnosis of the condition Shaping Landscape in South & East Asia
The neovascular age-related macular degeneration (nAMD) treatment market is turning out to be promising in the South & East Asia region. The prevalence of nAMD is increasing in the region due to aging populations, changing lifestyles, and increasing prevalence of diabetes.
Several pharmaceutical companies have been focusing on expanding their market presence in the region by investing in research and development, strategic partnerships, and collaborations. For example, Novartis and Roche have been leading players in the nAMD treatment market in the region, and have been expanding their product portfolios and conducting clinical trials for new treatments.
In addition, the availability of biosimilars of anti-VEGF drugs has increased in the region, which has made treatment more affordable for patients. The use of biosimilars has also increased competition in the market, leading to more affordable treatment options. However, challenges remain in the region, including limited access to specialized ophthalmologists, inadequate healthcare infrastructure in some areas, and low awareness of nAMD and its treatment options among patients and healthcare providers.
Overall, the nAMD treatment market in South & East Asia is expected to continue growing in the coming years, driven by factors such as increasing patient awareness, expanding healthcare infrastructure, and the introduction of new treatments.
What are the Factors Boosting the Market for Neovascular Age-related Macular Degeneration Treatment in North America?
Increasing Focus on technological advancements driving demand for Neovascular Age-related Macular Degeneration Treatment in North America
The aging population in North America is contributing to the increasing prevalence of nAMD. According to the American Academy of Ophthalmology, more than 10 million Americans are affected by AMD, with nAMD accounting for a significant portion of these cases.
North America is at the forefront of research and development of new nAMD treatments, and the availability of advanced treatment options such as anti-VEGF drugs has contributed to the growth of the market. Additionally, the introduction of gene therapy and sustained-release drug delivery systems has further expanded treatment options.
The strong healthcare infrastructure in North America has contributed to the growth of the nAMD treatment market, with access to specialized ophthalmologists, well-equipped healthcare facilities, and advanced diagnostic and treatment technologies. The increasing awareness of nAMD and its treatment options among patients and healthcare providers has contributed to the growth of the market. Patients are now seeking earlier diagnosis and treatment, which has increased the demand for effective nAMD treatments.
Become a MarketNgage Insider
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
By Disease type, Which Segment is Likely to Account for a Significant Share?
Wet AMD segment to hold a significant share and push market growth
Wet AMD is likely to account for a significant share in the Neovascular Age-related Macular Degeneration Treatment market is Wet AMD. Wet AMD is a more severe form of the disease and can progress rapidly, causing severe vision loss or blindness if left untreated.
This has led to a higher demand for treatments that can effectively manage the condition, such as anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are used to block the growth of abnormal blood vessels and reduce fluid leakage in the retina, slowing down the progression of the disease and improving vision.
By State of Disease, Which Segment is Likely to Account for a Significant Share?
Late-stage AMD segment to hold a significant share and push market growth
Among the different stages of AMD, the Late-stage AMD segment is likely to account for a significant share in the neovascular age-related macular degeneration treatment market.
Late-stage AMD includes both wet AMD and geographic atrophy, which are advanced forms of the disease that can cause severe vision loss or blindness if left untreated. As a result, there is a higher demand for effective treatments for late-stage AMD, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, which can help slow down the progression of the disease and improve vision.
Market Competition
Key players in the market include companies such as Competition Deep Dive, Competition Deep Dive, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc., ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc.GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals Inc. along with healthcare providers and technology companies among other global players.
- Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant was granted FDA approval on October 22, 2021. This approval is for the treatment of wet or neovascular age-related macular degeneration (AMD) in individuals who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a leading cause of blindness in people aged 60 and older and affects approximately 1.1 million people in the United States.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 3 billion |
|
Market Value in 2033 |
US$ 4.89 billion |
|
Growth Rate |
CAGR of 5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Neovascular Age-related Macular Degeneration Treatment Industry Survey
Drug Type:
- Ranibizumab
- Aflibercept
- Bevacizumab
- Brolucizumab
- Faricimab
Disease Type:
- Dry AMD
- Wet AMD
Age Group:
- Less than 60
- Between 60 to 80
- More than 80
Gender:
- Male
- Female
Stage of Disease:
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
Distribution Channel:
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
Region:North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
At what rate did the neovascular age-related macular degeneration treatment market flourish from 2018 to 2022?
From 2018 to 2022, the neovascular age-related macular degeneration treatment market grew at a CAGR of 3.5%.
What will be the growth rate of the global neovascular age-related macular degeneration treatment market during the forecast period?
The global neovascular age-related macular degeneration treatment market is expected to grow with a 5% CAGR from 2023 to 2033.
What will be the projected market size of the neovascular age-related macular degeneration treatment market by 2033?
As of 2033, the neovascular age-related macular degeneration treatment market is expected to reach US$ 4.89 Billion
Which therapy is expected to dominate the global neovascular age-related macular degeneration treatment market during 2033?
According to the FMI analysis, the topical therapy segment accounts for the largest market share.
How is the North American neovascular age-related macular degeneration treatment market projected to grow in 2033?
North America is expected to possess 40% market share for the neovascular age-related macular degeneration treatment market.
Table of Content
1. Executive Summary | Neovascular Age-related Macular Degeneration Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Ranibizumab 5.3.2. Aflibercept 5.3.3. Bevacizumab 5.3.4. Brolucizumab 5.3.5. Faricimab 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 6.3.1. Dry AMD 6.3.2. Wet AMD 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033 7.3.1. Less Than 60 7.3.2. Between 60 to 80 7.3.3. More Than 80 7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033 8.3.1. Male 8.3.2. Female 8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Stage of Disease, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage of Disease, 2023 to 2033 9.3.1. Early-stage AMD 9.3.2. Intermediate AMD 9.3.3. Late-stage AMD 9.4. Y-o-Y Growth Trend Analysis By Stage of Disease, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Stage of Disease, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacy 10.3.2. Specialty Pharmacy 10.3.3. Online Pharmacy 10.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 10.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. South Asia 11.3.5. East Asia 11.3.6. Oceania 11.3.7. MEA 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. United States 12.2.1.2. Canada 12.2.2. By Drug Type 12.2.3. By Disease Type 12.2.4. By Age Group 12.2.5. By Gender 12.2.6. By Stage of Disease 12.2.7. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Disease Type 12.3.4. By Age Group 12.3.5. By Gender 12.3.6. By Stage of Disease 12.3.7. By Distribution Channel 12.4. Key Takeaways 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Brazil 13.2.1.2. Mexico 13.2.1.3. Rest of Latin America 13.2.2. By Drug Type 13.2.3. By Disease Type 13.2.4. By Age Group 13.2.5. By Gender 13.2.6. By Stage of Disease 13.2.7. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Disease Type 13.3.4. By Age Group 13.3.5. By Gender 13.3.6. By Stage of Disease 13.3.7. By Distribution Channel 13.4. Key Takeaways 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Germany 14.2.1.2. United Kingdom 14.2.1.3. France 14.2.1.4. Spain 14.2.1.5. Italy 14.2.1.6. Rest of Europe 14.2.2. By Drug Type 14.2.3. By Disease Type 14.2.4. By Age Group 14.2.5. By Gender 14.2.6. By Stage of Disease 14.2.7. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Disease Type 14.3.4. By Age Group 14.3.5. By Gender 14.3.6. By Stage of Disease 14.3.7. By Distribution Channel 14.4. Key Takeaways 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. India 15.2.1.2. Malaysia 15.2.1.3. Singapore 15.2.1.4. Thailand 15.2.1.5. Rest of South Asia 15.2.2. By Drug Type 15.2.3. By Disease Type 15.2.4. By Age Group 15.2.5. By Gender 15.2.6. By Stage of Disease 15.2.7. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Disease Type 15.3.4. By Age Group 15.3.5. By Gender 15.3.6. By Stage of Disease 15.3.7. By Distribution Channel 15.4. Key Takeaways 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. China 16.2.1.2. Japan 16.2.1.3. South Korea 16.2.2. By Drug Type 16.2.3. By Disease Type 16.2.4. By Age Group 16.2.5. By Gender 16.2.6. By Stage of Disease 16.2.7. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Type 16.3.3. By Disease Type 16.3.4. By Age Group 16.3.5. By Gender 16.3.6. By Stage of Disease 16.3.7. By Distribution Channel 16.4. Key Takeaways 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. Australia 17.2.1.2. New Zealand 17.2.2. By Drug Type 17.2.3. By Disease Type 17.2.4. By Age Group 17.2.5. By Gender 17.2.6. By Stage of Disease 17.2.7. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Drug Type 17.3.3. By Disease Type 17.3.4. By Age Group 17.3.5. By Gender 17.3.6. By Stage of Disease 17.3.7. By Distribution Channel 17.4. Key Takeaways 18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 18.2.1. By Country 18.2.1.1. GCC Countries 18.2.1.2. South Africa 18.2.1.3. Israel 18.2.1.4. Rest of MEA 18.2.2. By Drug Type 18.2.3. By Disease Type 18.2.4. By Age Group 18.2.5. By Gender 18.2.6. By Stage of Disease 18.2.7. By Distribution Channel 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.2. By Drug Type 18.3.3. By Disease Type 18.3.4. By Age Group 18.3.5. By Gender 18.3.6. By Stage of Disease 18.3.7. By Distribution Channel 18.4. Key Takeaways 19. Key Countries Market Analysis 19.1. U.S. 19.1.1. Pricing Analysis 19.1.2. Market Share Analysis, 2022 19.1.2.1. By Drug Type 19.1.2.2. By Disease Type 19.1.2.3. By Age Group 19.1.2.4. By Gender 19.1.2.5. By Stage of Disease 19.1.2.6. By Distribution Channel 19.2. Canada 19.2.1. Pricing Analysis 19.2.2. Market Share Analysis, 2022 19.2.2.1. By Drug Type 19.2.2.2. By Disease Type 19.2.2.3. By Age Group 19.2.2.4. By Gender 19.2.2.5. By Stage of Disease 19.2.2.6. By Distribution Channel 19.3. Brazil 19.3.1. Pricing Analysis 19.3.2. Market Share Analysis, 2022 19.3.2.1. By Drug Type 19.3.2.2. By Disease Type 19.3.2.3. By Age Group 19.3.2.4. By Gender 19.3.2.5. By Stage of Disease 19.3.2.6. By Distribution Channel 19.4. Mexico 19.4.1. Pricing Analysis 19.4.2. Market Share Analysis, 2022 19.4.2.1. By Drug Type 19.4.2.2. By Disease Type 19.4.2.3. By Age Group 19.4.2.4. By Gender 19.4.2.5. By Stage of Disease 19.4.2.6. By Distribution Channel 19.5. Germany 19.5.1. Pricing Analysis 19.5.2. Market Share Analysis, 2022 19.5.2.1. By Drug Type 19.5.2.2. By Disease Type 19.5.2.3. By Age Group 19.5.2.4. By Gender 19.5.2.5. By Stage of Disease 19.5.2.6. By Distribution Channel 19.6. U.K. 19.6.1. Pricing Analysis 19.6.2. Market Share Analysis, 2022 19.6.2.1. By Drug Type 19.6.2.2. By Disease Type 19.6.2.3. By Age Group 19.6.2.4. By Gender 19.6.2.5. By Stage of Disease 19.6.2.6. By Distribution Channel 19.7. France 19.7.1. Pricing Analysis 19.7.2. Market Share Analysis, 2022 19.7.2.1. By Drug Type 19.7.2.2. By Disease Type 19.7.2.3. By Age Group 19.7.2.4. By Gender 19.7.2.5. By Stage of Disease 19.7.2.6. By Distribution Channel 19.8. Spain 19.8.1. Pricing Analysis 19.8.2. Market Share Analysis, 2022 19.8.2.1. By Drug Type 19.8.2.2. By Disease Type 19.8.2.3. By Age Group 19.8.2.4. By Gender 19.8.2.5. By Stage of Disease 19.8.2.6. By Distribution Channel 19.9. Italy 19.9.1. Pricing Analysis 19.9.2. Market Share Analysis, 2022 19.9.2.1. By Drug Type 19.9.2.2. By Disease Type 19.9.2.3. By Age Group 19.9.2.4. By Gender 19.9.2.5. By Stage of Disease 19.9.2.6. By Distribution Channel 19.10. India 19.10.1. Pricing Analysis 19.10.2. Market Share Analysis, 2022 19.10.2.1. By Drug Type 19.10.2.2. By Disease Type 19.10.2.3. By Age Group 19.10.2.4. By Gender 19.10.2.5. By Stage of Disease 19.10.2.6. By Distribution Channel 19.11. Malaysia 19.11.1. Pricing Analysis 19.11.2. Market Share Analysis, 2022 19.11.2.1. By Drug Type 19.11.2.2. By Disease Type 19.11.2.3. By Age Group 19.11.2.4. By Gender 19.11.2.5. By Stage of Disease 19.11.2.6. By Distribution Channel 19.12. Singapore 19.12.1. Pricing Analysis 19.12.2. Market Share Analysis, 2022 19.12.2.1. By Drug Type 19.12.2.2. By Disease Type 19.12.2.3. By Age Group 19.12.2.4. By Gender 19.12.2.5. By Stage of Disease 19.12.2.6. By Distribution Channel 19.13. Thailand 19.13.1. Pricing Analysis 19.13.2. Market Share Analysis, 2022 19.13.2.1. By Drug Type 19.13.2.2. By Disease Type 19.13.2.3. By Age Group 19.13.2.4. By Gender 19.13.2.5. By Stage of Disease 19.13.2.6. By Distribution Channel 19.14. China 19.14.1. Pricing Analysis 19.14.2. Market Share Analysis, 2022 19.14.2.1. By Drug Type 19.14.2.2. By Disease Type 19.14.2.3. By Age Group 19.14.2.4. By Gender 19.14.2.5. By Stage of Disease 19.14.2.6. By Distribution Channel 19.15. Japan 19.15.1. Pricing Analysis 19.15.2. Market Share Analysis, 2022 19.15.2.1. By Drug Type 19.15.2.2. By Disease Type 19.15.2.3. By Age Group 19.15.2.4. By Gender 19.15.2.5. By Stage of Disease 19.15.2.6. By Distribution Channel 19.16. South Korea 19.16.1. Pricing Analysis 19.16.2. Market Share Analysis, 2022 19.16.2.1. By Drug Type 19.16.2.2. By Disease Type 19.16.2.3. By Age Group 19.16.2.4. By Gender 19.16.2.5. By Stage of Disease 19.16.2.6. By Distribution Channel 19.17. Australia 19.17.1. Pricing Analysis 19.17.2. Market Share Analysis, 2022 19.17.2.1. By Drug Type 19.17.2.2. By Disease Type 19.17.2.3. By Age Group 19.17.2.4. By Gender 19.17.2.5. By Stage of Disease 19.17.2.6. By Distribution Channel 19.18. New Zealand 19.18.1. Pricing Analysis 19.18.2. Market Share Analysis, 2022 19.18.2.1. By Drug Type 19.18.2.2. By Disease Type 19.18.2.3. By Age Group 19.18.2.4. By Gender 19.18.2.5. By Stage of Disease 19.18.2.6. By Distribution Channel 19.19. GCC Countries 19.19.1. Pricing Analysis 19.19.2. Market Share Analysis, 2022 19.19.2.1. By Drug Type 19.19.2.2. By Disease Type 19.19.2.3. By Age Group 19.19.2.4. By Gender 19.19.2.5. By Stage of Disease 19.19.2.6. By Distribution Channel 19.20. South Africa 19.20.1. Pricing Analysis 19.20.2. Market Share Analysis, 2022 19.20.2.1. By Drug Type 19.20.2.2. By Disease Type 19.20.2.3. By Age Group 19.20.2.4. By Gender 19.20.2.5. By Stage of Disease 19.20.2.6. By Distribution Channel 19.21. Israel 19.21.1. Pricing Analysis 19.21.2. Market Share Analysis, 2022 19.21.2.1. By Drug Type 19.21.2.2. By Disease Type 19.21.2.3. By Age Group 19.21.2.4. By Gender 19.21.2.5. By Stage of Disease 19.21.2.6. By Distribution Channel 20. Market Structure Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Market Share Analysis of Top Players 20.3.1. By Regional 20.3.2. By Drug Type 20.3.3. By Disease Type 20.3.4. By Age Group 20.3.5. By Gender 20.3.6. By Stage of Disease 20.3.7. By Distribution Channel 21. Competition Analysis 21.1. Competition Deep Dive 21.1.1. F.Hoffmann-La Roche AG 21.1.1.1. Overview 21.1.1.2. Product Portfolio 21.1.1.3. Profitability by Market Segments 21.1.1.4. Sales Footprint 21.1.1.5. Strategy Overview 21.1.1.5.1. Marketing Strategy 21.1.2. Bausch + Lomb 21.1.2.1. Overview 21.1.2.2. Product Portfolio 21.1.2.3. Profitability by Market Segments 21.1.2.4. Sales Footprint 21.1.2.5. Strategy Overview 21.1.2.5.1. Marketing Strategy 21.1.3. Novartis AG 21.1.3.1. Overview 21.1.3.2. Product Portfolio 21.1.3.3. Profitability by Market Segments 21.1.3.4. Sales Footprint 21.1.3.5. Strategy Overview 21.1.3.5.1. Marketing Strategy 21.1.4. Pfizer Inc. 21.1.4.1. Overview 21.1.4.2. Product Portfolio 21.1.4.3. Profitability by Market Segments 21.1.4.4. Sales Footprint 21.1.4.5. Strategy Overview 21.1.4.5.1. Marketing Strategy 21.1.5. Allergan Plc. 21.1.5.1. Overview 21.1.5.2. Product Portfolio 21.1.5.3. Profitability by Market Segments 21.1.5.4. Sales Footprint 21.1.5.5. Strategy Overview 21.1.5.5.1. Marketing Strategy 21.1.6. Acucela Inc. 21.1.6.1. Overview 21.1.6.2. Product Portfolio 21.1.6.3. Profitability by Market Segments 21.1.6.4. Sales Footprint 21.1.6.5. Strategy Overview 21.1.6.5.1. Marketing Strategy 21.1.7. Santen Pharmaceuticals Co. 21.1.7.1. Overview 21.1.7.2. Product Portfolio 21.1.7.3. Profitability by Market Segments 21.1.7.4. Sales Footprint 21.1.7.5. Strategy Overview 21.1.7.5.1. Marketing Strategy 21.1.8. Ophthotech Corporation 21.1.8.1. Overview 21.1.8.2. Product Portfolio 21.1.8.3. Profitability by Market Segments 21.1.8.4. Sales Footprint 21.1.8.5. Strategy Overview 21.1.8.5.1. Marketing Strategy 21.1.9. Alimera Sciences Inc. 21.1.9.1. Overview 21.1.9.2. Product Portfolio 21.1.9.3. Profitability by Market Segments 21.1.9.4. Sales Footprint 21.1.9.5. Strategy Overview 21.1.9.5.1. Marketing Strategy 21.1.10. GSK plc. 21.1.10.1. Overview 21.1.10.2. Product Portfolio 21.1.10.3. Profitability by Market Segments 21.1.10.4. Sales Footprint 21.1.10.5. Strategy Overview 21.1.10.5.1. Marketing Strategy 21.1.11. Regeneron Pharmaceuticals Inc. 21.1.11.1. Overview 21.1.11.2. Product Portfolio 21.1.11.3. Profitability by Market Segments 21.1.11.4. Sales Footprint 21.1.11.5. Strategy Overview 21.1.11.5.1. Marketing Strategy 21.1.12. Bayer AG 21.1.12.1. Overview 21.1.12.2. Product Portfolio 21.1.12.3. Profitability by Market Segments 21.1.12.4. Sales Footprint 21.1.12.5. Strategy Overview 21.1.12.5.1. Marketing Strategy 21.1.13. RXi Pharmaceuticals Inc. 21.1.13.1. Overview 21.1.13.2. Product Portfolio 21.1.13.3. Profitability by Market Segments 21.1.13.4. Sales Footprint 21.1.13.5. Strategy Overview 21.1.13.5.1. Marketing Strategy 22. Assumptions & Acronyms Used 23. Research Methodology
Customize this Report
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 6: Global Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 7: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 11: North America Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 12: North America Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 13: North America Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 14: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 16: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 17: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 18: Latin America Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 19: Latin America Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 20: Latin America Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 21: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 22: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 24: Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 25: Europe Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 26: Europe Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 27: Europe Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 28: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 29: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 31: South Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 32: South Asia Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 33: South Asia Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 34: South Asia Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 35: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 36: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 38: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 39: East Asia Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 40: East Asia Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 41: East Asia Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 42: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 43: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 44: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 45: Oceania Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 46: Oceania Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 47: Oceania Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 48: Oceania Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 49: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 50: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 51: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 52: MEA Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033 Table 53: MEA Market Value (US$ Million) Forecast by Age Group , 2018 to 2033 Table 54: MEA Market Value (US$ Million) Forecast by Gender, 2018 to 2033 Table 55: MEA Market Value (US$ Million) Forecast by Stage of Disease, 2018 to 2033 Table 56: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Principal Consultant
Talk to Analyst
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Gender, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 6: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 7: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 17: Global Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 18: Global Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 19: Global Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 20: Global Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 21: Global Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 22: Global Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 23: Global Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 24: Global Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 25: Global Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 26: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 27: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 28: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 29: Global Market Attractiveness by Drug Type, 2023 to 2033 Figure 30: Global Market Attractiveness by Disease Type, 2023 to 2033 Figure 31: Global Market Attractiveness by Age Group , 2023 to 2033 Figure 32: Global Market Attractiveness by Gender, 2023 to 2033 Figure 33: Global Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 34: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 35: Global Market Attractiveness by Region, 2023 to 2033 Figure 36: North America Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 37: North America Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 38: North America Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 39: North America Market Value (US$ Million) by Gender, 2023 to 2033 Figure 40: North America Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 41: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 42: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 46: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 47: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 48: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 49: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 50: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 51: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 52: North America Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 53: North America Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 54: North America Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 55: North America Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 56: North America Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 57: North America Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 58: North America Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 59: North America Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 60: North America Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 61: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 62: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 63: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 64: North America Market Attractiveness by Drug Type, 2023 to 2033 Figure 65: North America Market Attractiveness by Disease Type, 2023 to 2033 Figure 66: North America Market Attractiveness by Age Group , 2023 to 2033 Figure 67: North America Market Attractiveness by Gender, 2023 to 2033 Figure 68: North America Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 69: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 70: North America Market Attractiveness by Country, 2023 to 2033 Figure 71: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 72: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 73: Latin America Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 74: Latin America Market Value (US$ Million) by Gender, 2023 to 2033 Figure 75: Latin America Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 76: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 77: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 78: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 79: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 80: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 81: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 82: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 83: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 84: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 85: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 86: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 87: Latin America Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 88: Latin America Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 89: Latin America Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 90: Latin America Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 91: Latin America Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 92: Latin America Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 93: Latin America Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 94: Latin America Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 95: Latin America Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 96: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 97: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 98: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 99: Latin America Market Attractiveness by Drug Type, 2023 to 2033 Figure 100: Latin America Market Attractiveness by Disease Type, 2023 to 2033 Figure 101: Latin America Market Attractiveness by Age Group , 2023 to 2033 Figure 102: Latin America Market Attractiveness by Gender, 2023 to 2033 Figure 103: Latin America Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 104: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 105: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 106: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 107: Europe Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 108: Europe Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 109: Europe Market Value (US$ Million) by Gender, 2023 to 2033 Figure 110: Europe Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 111: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 112: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 113: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 114: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 115: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 116: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 117: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 118: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 119: Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 120: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 121: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 122: Europe Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 123: Europe Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 124: Europe Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 125: Europe Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 126: Europe Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 127: Europe Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 128: Europe Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 129: Europe Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 130: Europe Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 131: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 132: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 133: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 134: Europe Market Attractiveness by Drug Type, 2023 to 2033 Figure 135: Europe Market Attractiveness by Disease Type, 2023 to 2033 Figure 136: Europe Market Attractiveness by Age Group , 2023 to 2033 Figure 137: Europe Market Attractiveness by Gender, 2023 to 2033 Figure 138: Europe Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 139: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 140: Europe Market Attractiveness by Country, 2023 to 2033 Figure 141: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 142: South Asia Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 143: South Asia Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 144: South Asia Market Value (US$ Million) by Gender, 2023 to 2033 Figure 145: South Asia Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 146: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 147: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 148: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 149: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 150: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 151: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 152: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 153: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 154: South Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 155: South Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 156: South Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 157: South Asia Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 158: South Asia Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 159: South Asia Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 160: South Asia Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 161: South Asia Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 162: South Asia Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 163: South Asia Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 164: South Asia Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 165: South Asia Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 166: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 167: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 168: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 169: South Asia Market Attractiveness by Drug Type, 2023 to 2033 Figure 170: South Asia Market Attractiveness by Disease Type, 2023 to 2033 Figure 171: South Asia Market Attractiveness by Age Group , 2023 to 2033 Figure 172: South Asia Market Attractiveness by Gender, 2023 to 2033 Figure 173: South Asia Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 174: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 175: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 176: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 177: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 178: East Asia Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 179: East Asia Market Value (US$ Million) by Gender, 2023 to 2033 Figure 180: East Asia Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 181: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 182: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 183: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 184: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 185: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 186: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 187: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 188: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 189: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 190: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 191: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 192: East Asia Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 193: East Asia Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 194: East Asia Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 195: East Asia Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 196: East Asia Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 197: East Asia Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 198: East Asia Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 199: East Asia Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 200: East Asia Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 201: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 202: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 203: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 204: East Asia Market Attractiveness by Drug Type, 2023 to 2033 Figure 205: East Asia Market Attractiveness by Disease Type, 2023 to 2033 Figure 206: East Asia Market Attractiveness by Age Group , 2023 to 2033 Figure 207: East Asia Market Attractiveness by Gender, 2023 to 2033 Figure 208: East Asia Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 209: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 210: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 211: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 212: Oceania Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 213: Oceania Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 214: Oceania Market Value (US$ Million) by Gender, 2023 to 2033 Figure 215: Oceania Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 216: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 217: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 218: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 219: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 220: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 221: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 222: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 223: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 224: Oceania Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 225: Oceania Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 226: Oceania Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 227: Oceania Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 228: Oceania Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 229: Oceania Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 230: Oceania Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 231: Oceania Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 232: Oceania Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 233: Oceania Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 234: Oceania Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 235: Oceania Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 236: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 237: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 238: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 239: Oceania Market Attractiveness by Drug Type, 2023 to 2033 Figure 240: Oceania Market Attractiveness by Disease Type, 2023 to 2033 Figure 241: Oceania Market Attractiveness by Age Group , 2023 to 2033 Figure 242: Oceania Market Attractiveness by Gender, 2023 to 2033 Figure 243: Oceania Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 244: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 245: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 246: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 247: MEA Market Value (US$ Million) by Disease Type, 2023 to 2033 Figure 248: MEA Market Value (US$ Million) by Age Group , 2023 to 2033 Figure 249: MEA Market Value (US$ Million) by Gender, 2023 to 2033 Figure 250: MEA Market Value (US$ Million) by Stage of Disease, 2023 to 2033 Figure 251: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 252: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 253: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 254: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 255: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 256: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 257: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 258: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 259: MEA Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033 Figure 260: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033 Figure 261: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033 Figure 262: MEA Market Value (US$ Million) Analysis by Age Group , 2018 to 2033 Figure 263: MEA Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033 Figure 264: MEA Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033 Figure 265: MEA Market Value (US$ Million) Analysis by Gender, 2018 to 2033 Figure 266: MEA Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033 Figure 267: MEA Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033 Figure 268: MEA Market Value (US$ Million) Analysis by Stage of Disease, 2018 to 2033 Figure 269: MEA Market Value Share (%) and BPS Analysis by Stage of Disease, 2023 to 2033 Figure 270: MEA Market Y-o-Y Growth (%) Projections by Stage of Disease, 2023 to 2033 Figure 271: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 272: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 273: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 274: MEA Market Attractiveness by Drug Type, 2023 to 2033 Figure 275: MEA Market Attractiveness by Disease Type, 2023 to 2033 Figure 276: MEA Market Attractiveness by Age Group , 2023 to 2033 Figure 277: MEA Market Attractiveness by Gender, 2023 to 2033 Figure 278: MEA Market Attractiveness by Stage of Disease, 2023 to 2033 Figure 279: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 280: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
